MOUNTAIN VIEW, CA and TOKYO – Jan 28, 2008 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that the company recently signed a license agreement with Kirin Pharma Company, Limited for the exclusive worldwide rights to use Kirin’s clinical stage compound, KRN7000, formulated with a liposome.

KRN7000 is a biological response modifier that belongs to a chemical class called alpha-galactosylceramides, or alpha-GalCer. Originally isolated from a marine sponge, this compound was first investigated as a potential anti-cancer compound. KRN7000 was later found to act as a ligand for natural killer T (NKT) cells, exhibiting potent immunomodulatory activities. The compound has been extensively studied, with more than 1,000 scientific research papers published to date. Kirin Pharma had conducted clinical studies of KRN7000 for the treatment of cancer, as well as for hepatitis B and hepatitis C.

By incorporating KRN7000 into a specific liposomal formulation, REGiMMUNE has developed a proprietary, immunomodulatory platform technology, reVax, applicable to a broad range of immune disorders. reVax technology uniquely induces antigen-specific immune suppression via induction of regulatory T cells (or Tregs), a T cell subset that plays a central role in controlling immune responses to self-antigens and pathogens. REGiMMUNE’s reVax is the first and only available technology to pharmacologically enhance the function of Tregs. Induced by reVax, Tregs downregulate pathologic immune responses and maintain a fine balance between immune activation and immune suppression to a given antigen. Further, because of the antigen-specific manner of immune suppression, reVax products are anticipated to maintain the body’s normal immune function.

REGiMMUNE applies reVax technology to develop drugs for the treatment of various immune disorders, including allergy, such as cedar pollen allergy, graft versus host disease (GvHD) associated with bone marrow transplantation, solid organ transplantation, and autoimmune diseases. In addition to pursuing the company’s in-house drug development programs, REGiMMUNE is actively seeking collaboration partners to apply its reVax platform technology to partner’s antigens/ allergens or its field of interest.

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company’s proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California.


Debra Bannister
530 676-8001